Abstract
The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance in vitro , ceftazidime-avibactam previously demonstrated in vivo activity against NDM-positive Enterobacteriaceae . Herein, we observed in vitro synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM. In vivo , humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log 10 CFU bacterial reduction; therefore, no in vivo synergy was observed.
Cite
CITATION STYLE
Monogue, M. L., Abbo, L. M., Rosa, R., Camargo, J. F., Martinez, O., Bonomo, R. A., & Nicolau, D. P. (2017). In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 61(7). https://doi.org/10.1128/aac.00486-17
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.